TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC
Resource
J. Thorac. Oncol., 10(9), S427-S427
Journal
J. Thorac. Oncol.
Journal Volume
10
Journal Issue
9
Pages
-
Date Issued
2015
Date
2015
Author(s)
Camidge, Ross
Cappuzzo, Federico
Go, Jowell
Isaacson, Jeffrey
Litten, Jason
Park, Keunchil
Spigel, David R.
Spira, Alexander
Vergnenegre, Alain
Wolf, Juergen
Yang, James Chih-Hsin
Mok, Tony
Subjects
T790M
rociletinib
EGFR
NSCLC